2013-03-08-世界卫生组织-INN_Recommended_List_69_53页_527kb

Summary of International Nonproprietary Names for Pharmaceutical Substances (INN) - List 69

Core Content

This document provides a list of Recommended International Nonproprietary Names (INN) for pharmaceutical substances, specifically List 69, as established by the World Health Organization (WHO). These names are used for the identification of pharmaceutical substances in an international context and are not indicative of any recommendation regarding the medical use of the substances.

The document includes French (DCI) and Spanish (DCI) versions of the names, alongside the chemical names, molecular formulas, and graphic formulas of the substances. Additionally, it provides structural details, such as disulfide bridge locations, N-glycosylation sites, and amino acid sequences for certain compounds.

Main Points

1. INN and DCI Overview

• INN is the official name for pharmaceutical substances.
• DCI is the French equivalent of INN.
• DCI in Spanish is also used.
• The inclusion of a name in the list does not imply any medical or pharmaceutical recommendation.

2. Key Substances Listed

• Actoxumabum / Actoxumab

  • A monoclonal antibody targeting Clostridium difficile toxin A.
  • Molecular formula: C12H13NO4S.
  • Structural details include disulfide bridges and N-glycosylation sites.

• Alirocumabum / Alirocumab

  • A monoclonal antibody targeting Homo sapiens PCSK9.
  • Molecular formula: C29H34Cl2N4O4.
  • Includes disulfide bridges and N-glycosylation sites.

• Bezlotoxumabum / Bezlotoxumab

  • A monoclonal antibody targeting Clostridium difficile toxin B.
  • Molecular formula: C29H34Cl2N4O4.
  • Structural information includes disulfide bridges and N-glycosylation sites.

• Blisibimodum / Blisibimod

  • A fusion protein combining human IgG1 Fc and a BAFF-binding peptide.
  • Molecular formula: C24H27FN2O.
  • Contains disulfide bridges and N-glycosylation sites.

• Burlulipasum / Burlulipase

  • A lipase with a common amino acid sequence in Burkholderia plantarii and Burkholderia glumae.
  • Molecular formula: C24H27FN2O.
  • Includes disulfide bridge locations.

• Cindunistatum / Cindunistat

  • A compound with the formula S-[2-(acetimidoylamino)ethyl]-2-methyl-L-cysteine.
  • Molecular formula: C11H19N3O2S.

• Clazakizumabum / Clazakizumab

  • A humanized monoclonal antibody targeting Homo sapiens IL6.
  • Molecular formula: C21H21F3IN3O2.
  • Contains disulfide bridges and N-glycosylation sites.

• Cobimetinibum / Cobimetinib

  • A kinase inhibitor with the formula [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone.
  • Molecular formula: C21H21F3IN3O2.

• Crisantaspasum / Crisantaspase

  • An L-asparaginase from Erwinia chrysanthemi.
  • Molecular formula: C1546H2510N432O476S9 (monomer).
  • It is a tetramer α4.

Key Information

• The recommended names are based on Resolution EB15.R7, EB43.R9, and EB115.R4.
• The Cumulative List No. 14, 2011 contains both proposed and recommended INN names, available only in CD-ROM format.
• The chemical names and molecular formulas provide detailed chemical identities.
• Disulfide bridges and N-glycosylation sites are essential structural features of some proteins, particularly monoclonal antibodies.
• The amino acid sequences and structural descriptions are provided for some compounds to clarify their molecular composition and structure.

Structure and Format

• The document is structured with tables and sections in Latin, English, French, and Spanish.
• Each entry includes:
  • Recommended INN.
  • Chemical name or description.
  • Molecular formula.
  • Graphic formula (in some cases).
  • Disulfide bridge locations.
  • N-glycosylation sites.
  • Amino acid sequences.

This summary captures the core content, main points, and key information from the document, ensuring clarity and conciseness.